PharmEasy Unlisted Share PricePharmEasy (API Holdings Limited) · ₹6.95

API Holdings vs the PharmEasy brand

Searches for “PharmEasy shares” and “API Holdings shares” are the same listing on ShareSaathi. The legal issuer is API Holdings Limited (ISIN INE0DJ201029); PharmEasy is the consumer brand sitting under that holdco, alongside diagnostics (Thyrocare) and other healthcare verticals.

Quote the holdco ISIN on WhatsApp so the desk does not match a different healthcare or diagnostics name.

Why the PharmEasy share price looks low

The rupee ask (₹6.95 as of 10 Oct 2026 IST) is not a “cheap stock” signal by itself. After a sharp private-market reset and a large rights issue, the share count is much higher, so the per-share print is small even when market cap is not. There are about 702.6 Cr equity shares plus convertible preference shares; the company’s own EPS uses about 1,535 Cr shares, so FY2026 EPS was −₹0.37, not the −₹0.74 you get from equity shares alone.

Use the market cap (₹11,443.56 Cr) and the financials on this page — not a screenshot of an old round — before you size a lot of 5,000 shares (₹34,750).

Unlisted PharmEasy vs a public listing

A reverse merger into listed Thyrocare is one possible path to a public listing. In August 2026 management ruled it out for now: the conditions it gave are being debt-free, which it has since announced, and being profitable without leaning on Thyrocare’s numbers, which it targets by the end of FY2027. There is no filed scheme, and buying here is not an IPO allotment.

Pre-IPO / unlisted stock typically sits in a six-month lock-in from listing if a listing happens. This page is a bilateral off-market quote against ISIN INE0DJ201029.

About PharmEasy (API Holdings Limited) unlisted shares

API Holdings Limited is the parent company behind PharmEasy. It was founded in 2015 and is well known as a consumer brand, which is why “PharmEasy share price” is searched even though the company is unlisted. Most of the revenue now comes from distribution, not the app. Ascent / Retailio supplies chemists (68% of FY2026 product revenue), Aknamed supplies hospitals, the PharmEasy app sells medicines and lab tests, and Thyrocare, the listed diagnostics chain bought in 2021, earns most of the profit.

FY2026 consolidated revenue was ₹6,618.5 Cr. EBITDA turned positive for the first time at ₹38 Cr, and the net loss narrowed to ₹520 Cr from ₹5,211 Cr in FY2023. Rahul Guha, who also runs Thyrocare, has been MD and CEO since August 2025, with co-founder Siddharth Shah as Vice Chairman. On 14 August 2026 the group repaid its remaining ₹1,050 Cr of term debt, funded by selling down Thyrocare to 51.02%.

ShareSaathi’s PharmEasy (API Holdings) unlisted share price is ₹6.95 as of 10 Oct 2026 IST. One lot is 5,000 shares and the minimum investment is ₹34,750 at the ask. The listing on this page is the holding company API Holdings (ISIN INE0DJ201029) — quote this ISIN so the trade is unambiguous.

This is a turnaround / recovery story, not a clean growth compounder. PharmEasy’s private valuation was cut sharply from its peak, and it raised about ₹3,500 Cr through a Series B CCPS rights issue at ₹96.80 in 2023 to pay down debt. The low rupee price per share is a function of the share count after that reset, not a “cheap” signal on its own.

Buyers transact it as a bet on a possible eventual listing and a stabilising health-tech business. Read the financials on this page and treat brand recognition as marketing, not a floor price — a listing is not promised on any timeline.

Settlement is off-market demat, typically T+0, against ISIN INE0DJ201029. ShareSaathi confirms a lot, you pay after confirmation, complete KYC, and the shares credit to your demat.